STAR Protoc. 2026 Jul 17;7(3):104706. doi: 10.1016/j.xpro.2026.104706. Online ahead of print.

ABSTRACT

Here, we present a protocol for generating high-throughput, droplet-engineered tumor organoids from triple-negative breast cancer (TNBC) tissues using the OrgFab® micro-sphere printing system. We describe tumor dissociation, bioink preparation, and automated organoid fabrication. We further detail rho-associated coiled-coil kinase (ROCK) pathway modulation to preserve tumor-infiltrating lymphocytes (TILs) and enhance T cell function, as well as flow cytometry-based immune characterization (Figure 1). This protocol enables scalable production of immune-competent tumor organoids for immunological analysis and drug-screening applications. For complete details on the use and execution of this protocol, please refer to Zhou et al.¹.

PMID:42470642 | DOI:10.1016/j.xpro.2026.104706